Orexo US Inc
Orexo US Inc received $3.0M in federal prime contract obligations in the 12 months ending Oct 5, 2026, down 64.5% from $8.5M the year before, and $11.5M since FY2022. Its largest customer is the Department of Health and Human Services.
See 1 contracts ending in the next 18 months ↓Contractor details
- Unique Entity ID (UEI)
- MN1MPMBCVVD5
- CAGE code
- 6Y7L3
- Headquarters
- Morristown, NJ
- Business size
- Small Business
- Parent company
- Orexo AB (UEI G3NJFQBBMP39)
As recorded on this UEI's most recent prime contract action in USAspending.gov. Confirm current registration and certifications in SAM.gov.
Obligations by fiscal year
Net prime contract obligations by federal fiscal year.
Top agencies
Funding agencies ranked by obligations since FY2022.
| Funding agency | Latest 12 mo | Since FY2022 |
|---|---|---|
| Department of Health and Human Services | $3.0M | $11.5M |
Top NAICS codes
Industry codes agencies recorded on this contractor's awards, since FY2022.
| NAICS | Industry | Latest 12 mo | Since FY2022 |
|---|---|---|---|
| 541714 | Research and Development in Biotechnology (except Nanobiotechnology) | $3.0M | $11.5M |
What it sells
Product and service codes (PSC) on this contractor's awards, since FY2022.
| PSC | Description | Since FY2022 |
|---|---|---|
| AN13 | Health R&D services; Health Care services; Experimental Development | $11.5M |
Contracts ending in the next 18 months
This contractor's largest awards whose current period of performance ends soon. Options and extensions often move these dates.
| Award | Agency | Obligated | Current end |
|---|---|---|---|
| 75A50125C00010 | Department of Health and Human Services CLINICAL DEVELOPMENT OF OX390 (ATIPAMEZOLE) AS AN ?2 AGONIST REVERSAL AGENT FOR HUMAN USE TO COUNTERACT THE SEDATIVE EFFECTS OF XYLAZINE, MEDETOMIDINE, AND OTHER ?2 AGONISTS | $11.5M | Dec 31, 2027 |
Recent awards
This contractor's newest prime contract awards, most recent first.
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| 75A50125C00010 | Department of Health and Human Services CLINICAL DEVELOPMENT OF OX390 (ATIPAMEZOLE) AS AN ?2 AGONIST REVERSAL AGENT FOR HUMAN USE TO COUNTERACT THE SEDATIVE EFFECTS OF XYLAZINE, MEDETOMIDINE, AND OTHER ?2 AGONISTS | $8.5M | Sep 24, 2025 |
Prime contracts (award types A–D) from USAspending.gov through Oct 5, 2026. Subcontracts are not included. Net obligations include deobligations and corrections.
Ready to connect your pursuit work?
GovEagle gives BD directors, capture managers, and proposal teams one AI workspace from pipeline through proposal, with CMMC/FedRAMP Certified compliance built in.